Selskabets formål er at drive virksomhed med udvikling, produktion og handel til indenlandske og udenlandske kunder af vacciner og andre biologiske lægemidler samt anden virksomhed, der efter bestyrelsens skøn er forbundet dermed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 413 mio. | -807.1 mio. | 1.1 mia. | 501.9 mio. | 581 | |
CVR: 37911143
Previous names: Aktieselskabet af august 2016
Compared to 131 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
AJ Vaccines A/S is currently facing significant financial challenges, with a notable decline in profitability over the past few years. In 2024, the company reported a revenue of 412.97 million DKK but incurred a substantial loss of 807.12 million DKK, following a loss of 242.97 million DKK in 2023. Despite a slight increase in revenue from 351.86 million DKK in 2021 to 468.89 million DKK in 2023, the persistent losses raise concerns about its operational efficiency and cost management. The equity position has decreased from 1.05 billion DKK in 2020 to 501.92 million DKK in 2024, indicating a weakening financial foundation. As a player in the pharmaceutical manufacturing industry, AJ Vaccines A/S must address these issues to stabilize its financial health and improve its market position.
AI-generated summary
Companies in the same industry and area
companydata.dk